BioRestorative Therapies, Inc. announced that effective as of November 16, 2020 (the Effective Date of the Plan), as contemplated by the Plan, Mark Weinreb, A. Jeffrey Radov, Paul Jude Tonna and Robert B. Catell resigned as directors of the Company and Mr. Weinreb resigned as President and Chairman of the Board of the Company. Effective as of the Effective Date, as contemplated by the Plan, Lance Alstodt was elected President and Chairman of the Board and a director of the Company and Francisco Silva, the Company’s Vice President, Research and Development, was elected a director of the Company. Mr. Alstodt, age 50, served as Executive Vice President and Chief Strategy Officer of the Company from October 2018 to February 2020. He is a senior healthcare executive with over 25 years of experience in the medical device, biopharmaceutical and healthcare services sectors. In 2013, Mr. Alstodt founded and became CEO of MedVest Consulting Corporation (“MedVest”), an advisory and capital firm that was formed to focus exclusively on the healthcare industry. Prior to Medvest, he was a career investment banker with over 20 years of experience with respect to acquisitions, leveraged buyouts, private and public financings, exclusive sales, takeover defenses, joint ventures, restructurings and general advisory services.